Tiziana Life Sciences Expands Phase 2 SPMS Trial
Ticker: TLSA · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1723069
Sentiment: neutral
Topics: clinical-trial, expansion, multiple-sclerosis, drug-development
TL;DR
Tiziana Life Sciences is expanding its Phase 2 SPMS trial for intranasal foralumab, adding more sites.
AI Summary
On December 4, 2024, Tiziana Life Sciences LTD announced the expansion of its Phase 2 clinical trial for intranasal foralumab. This trial is evaluating the drug's efficacy in treating non-active secondary progressive multiple sclerosis (SPMS) and will include additional trial sites at esteemed institutions.
Why It Matters
The expansion of this clinical trial is a crucial step in potentially bringing a new treatment option to patients suffering from a debilitating form of multiple sclerosis.
Risk Assessment
Risk Level: medium — Clinical trial expansions are positive but the success of the drug is not yet guaranteed, carrying inherent biotech risks.
Key Players & Entities
- Tiziana Life Sciences LTD (company) — Registrant
- foralumab (drug) — Investigational drug
- December 4, 2024 (date) — Announcement date
- secondary progressive multiple sclerosis (SPMS) (disease) — Condition being treated
FAQ
What is the purpose of the expanded Phase 2 clinical trial?
The expanded Phase 2 clinical trial is evaluating intranasal foralumab for non-active secondary progressive multiple sclerosis (SPMS).
When was this expansion announced?
The expansion was announced on December 4, 2024.
What is the drug being tested?
The drug being tested is intranasal foralumab.
What condition is the drug intended to treat?
The drug is intended to treat non-active secondary progressive multiple sclerosis (SPMS).
Where are the new trial sites located?
The filing states the trial sites include esteemed institutions across the country, but does not specify exact locations.
Filing Stats: 327 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-12-04 07:00:07
Filing Documents
- ea0223489-6k_tiziana.htm (6-K) — 13KB
- ea022348901ex99-1_tiziana.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-105236.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: December 4, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated December 4, 2024 3